Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
Phase 1/2 Withdrawn
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Phase 1/2 Withdrawn
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
Phase NA Withdrawn
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
Phase 1/2 Withdrawn
pediTACTAL
Phase 1 Withdrawn
HMvax-Regist
Withdrawn
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Phase NA Withdrawn
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Phase 3 Withdrawn
Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies
Phase 2 Withdrawn
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas
Phase 1 Withdrawn
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
Phase 1/2 Withdrawn
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
LEO
Withdrawn
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
Phase 1 Withdrawn
Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study
Withdrawn
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3 Withdrawn
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
Phase 1 Withdrawn
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Phase 2/3 Withdrawn
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Phase 1 Withdrawn
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
Phase 1 Withdrawn
STP-LYM-01
Phase 1/2 Withdrawn
CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)
Phase 1 Withdrawn
Long-term Registry of Patients Treated With Loncastuximab Tesirine
Withdrawn
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
Collecting and Storing Blood Samples From Patients With Cancer
Withdrawn
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Phase 1/2 Withdrawn
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Phase 2 Withdrawn
R-CHOP-OS
Withdrawn
Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
Phase 3 Withdrawn
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
Phase 1 Withdrawn
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Phase 1 Withdrawn
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Phase 1 Withdrawn
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Phase 1 Withdrawn
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
Phase 1 Withdrawn
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Withdrawn
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Phase 1 Withdrawn
Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Phase 1 Withdrawn
Providing Access to Cord Blood Units for Transplants
Phase 2 Withdrawn
Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
Phase 2 Withdrawn
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Phase 2 Withdrawn
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Phase 1 Withdrawn
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Withdrawn
Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer
Withdrawn
ABC-102
Phase 1/2 Withdrawn
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Phase 2 Withdrawn
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Phase 2 Withdrawn
COMBOSTAT
Phase 2 Withdrawn
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Phase 1/2 Withdrawn
Prospective Study of Lymphoproliferative Diseases
Withdrawn
Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant
Phase 2 Withdrawn